<DOC>
	<DOCNO>NCT01344837</DOCNO>
	<brief_summary>This research study study biomarkers blood tissue sample patient uterine cancer . Studying sample blood tissue patient cancer laboratory may help doctor learn change occur DNA identify biomarkers related cancer .</brief_summary>
	<brief_title>Biomarkers Blood Tissue Samples From Patients With Uterine Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine whether synuclein-γ ( SNCG ) expression primary tumor associate overall survival ( OS ) uterine papillary serous carcinoma ( UPSC ) patient . SECONDARY OBJECTIVES : I . Determine whether SNCG expression associate clinical covariates ( age diagnosis , race , surgical stage , depth myometrial invasion , presence lymph vascular space invasion , lymph node status , location extrauterine disease , chemotherapy , radiation therapy ) UPSC patient . II . Determine whether SNCG expression associate biomarker expression , include TP53 ( p53 ) , HER-2 , folate receptor alpha ( FOLR1 ) , estrogen receptor ( ER ) , progesterone receptor ( PR ) , phosphatase tensin homolog ( PTEN ) , phosphorylated AKT ( pAKT ) , pERK , p16 primary tumor tissue . III . Determine whether SNCG expression associate progression-free survival ( PFS ) . IV . Determine whether SNCG expression associate synchronous metachronous breast cancer . EXPLORATORY OBJECTIVES : I . Determine whether SNCG detect serum UPSC patient . II . Determine whether serum SNCG UPSC patient differs normal healthy control woman woman endometrioid endometrial cancer . III . Determine whether serum SNCG UPSC patient associate overall survival ( OS ) , clinical covariates ( list ) , tumor expression biomarkers ( list ) , PFS , synchronous metachronous breast cancer . IV . Develop prediction model panel biomarkers clinical prognostic factor OS , PFS , synchronous metachronous breast cancer UPSC patient . OUTLINE : Archived serum tumor tissue sample analyze synuclein-γ ( SNCG ) expression biomarker expression , include TP53 ( p53 ) , HER-2 , folate receptor alpha ( FOLR1 ) , estrogen receptor ( ER ) , progesterone receptor ( PR ) , phosphatase tensin homolog ( PTEN ) , phosphorylated AKT ( pAKT ) , pERK , p16 microarray analysis , IHC assay , western blot . Results compare patient ' exist clinical , demographic , pathology data , include history breast cancer ( metachronous ) breast cancer diagnose time endometrial cancer ( synchronous ) .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Uterine Neoplasms</mesh_term>
	<mesh_term>Cystadenocarcinoma , Serous</mesh_term>
	<criteria>Women uterine papillary serous carcinoma ( UPSC ) eligible GOG0210 protocol , molecular staging study endometrial cancer , GOG0136 , general specimen bank study gynecologic cancer , consent future research , histologicallyconfirmed UPSC stage , satisfactory formalinfixed paraffinembedded primary tumor without satisfactory preoperative serum specimen available test Women endometrioid endometrial cancer eligible GOG0210 GOG0136 , consent future research , histologicallyconfirmed endometrioid endometrial carcinoma similar stage , age race/ethnicity distribution UPSC patient , satisfactory formalinfixed paraffinembedded primary tumor and/or preoperative serum specimen available test Normal healthy control woman participate Biopathology protocol banking serum normal healthy control woman , consented future research , cancer history cancer similar age race/ethnicity distribution UPSC patient satisfactory serum available test</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>